<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35238053</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1096-9071</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>94</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of medical virology</Title>
          <ISOAbbreviation>J Med Virol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID.</ArticleTitle>
        <Pagination>
          <StartPage>3416</StartPage>
          <EndPage>3420</EndPage>
          <MedlinePgn>3416-3420</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27689</ELocationID>
        <Abstract>
          <AbstractText>Coronavirus disease 2019 (COVID-19) is spreading worldwide; there is a need to address its sequelae known as Long COVID. This study evaluated postvaccination changes in symptoms and antibody titers in patients with Long COVID. Patients visiting the outpatient department specializing in Long COVID at our hospital were enrolled. Changes in symptoms were evaluated before and 14-21 days after first vaccination. Antibody titers were measured using ARCHITECT SARS-CoV-2 IgG II Quant at the same time. This study included 42 patients (median age: 45 years; 17 [40.5%] men). Median pre- and postvaccination antibody titers were 456 and 28,963 AU/ml, respectively. Postvaccination symptoms (fatigue, joint pain, and taste and olfactory abnormalities) were relieved, worsened, and unchanged in 7 (16.7%), 9 (21.4%), and 26 (61.9%) patients, respectively. Ratios of pre- and postvaccination antibody titers were 53, 40, and 174 in the unchanged, relief, and worsened groups, respectively. The worsened group had the significantly highest antibody titer ratio (p = 0.02). The higher increased rate of the antibody titer in the worsened group than in the nonworsened group suggests an excessive immune response to vaccination associated with worsening of sequelae. Although patients with Long COVID should be vaccinated, additional concerns should be addressed.</AbstractText>
          <CopyrightInformation>© 2022 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tsuchida</LastName>
            <ForeName>Tomoya</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-8517-3941</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, St. Marianna University School of Medicine, Division of General Internal Medicine, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirose</LastName>
            <ForeName>Masanori</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, St. Marianna University School of Medicine, Division of General Internal Medicine, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Inoue</LastName>
            <ForeName>Yoko</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, St. Marianna University School of Medicine, Division of General Internal Medicine, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kunishima</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Infectious Diseases, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Otsubo</LastName>
            <ForeName>Takehito</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuda</LastName>
            <ForeName>Takahide</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, St. Marianna University School of Medicine, Division of General Internal Medicine, Kawasaki, Kanagawa, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Med Virol</MedlineTA>
        <NlmUniqueID>7705876</NlmUniqueID>
        <ISSNLinking>0146-6615</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C000711409">post-acute COVID-19 syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Long COVID</Keyword>
        <Keyword MajorTopicYN="N">antibody titer</Keyword>
        <Keyword MajorTopicYN="N">vaccine</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35238053</ArticleId>
        <ArticleId IdType="pmc">PMC9088489</ArticleId>
        <ArticleId IdType="doi">10.1002/jmv.27689</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Ministry of Health, Labour and Welfare
. Domestic outbreaks, etc. Accessed December 11, 2021. https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html
</Citation>
        </Reference>
        <Reference>
          <Citation>
Prime Minister's Office of Japan
. About the novel coronavirus vaccines in Japan. Accessed December 10, 2021. https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html
</Citation>
        </Reference>
        <Reference>
          <Citation>
World Health Organization
. A clinical case definition of post COVID‐19 condition by a Delphi consensus. October 6, 2021. Accessed November 21, 2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
Huang C, Huang L, Wang Y, et al. 6‐month consequences of COVID‐19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220‐232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7833295</ArticleId>
            <ArticleId IdType="pubmed">33428867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huang L, Yao Q, Gu X, et al. 1‐year outcomes in hospital survivors with COVID‐19: a longitudinal cohort study. Lancet. 2021;398:747‐758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8389999</ArticleId>
            <ArticleId IdType="pubmed">34454673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miyazato Y, Tsuzuki S, Morioka S, et al. Risk factors associated with development and persistence of Long COVID. Medrxiv. 2021;7:ofaa507. 10.1101/2021.09.22.21263998
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.09.22.21263998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post‐vaccination SARS‐CoV‐2 infection in UK users of the COVID Symptom Study app: a prospective, community‐based, nested, case‐control study. Lancet Infect Dis. 2021;22:43‐55. 10.1016/S1473-3099(21)00460-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId>
            <ArticleId IdType="pmc">PMC8409907</ArticleId>
            <ArticleId IdType="pubmed">34480857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Long CovidSOS
. The impact of COVID vaccination on symptoms of Long Covid. An international survey of 900 people with lived experience. May 2021. Accessed November 21, 2021. https://3ca26cd7-266e-4609-b25f-6f3d1497c4cf.filesusr.com/ugd/8bd4fe_7301ed588cc44d1483e9fc8df7989a03.pdf
</Citation>
        </Reference>
        <Reference>
          <Citation>
Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms after COVID‐19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med. 2021;174:1334‐1336.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8252827</ArticleId>
            <ArticleId IdType="pubmed">34029484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pramesh CS, Babu GR, Basu J, et al. Choosing wisely for COVID‐19: ten evidence‐based recommendations for patients and physicians. Nat Med. 2021;27:1324‐1327.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34226738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS‐CoV‐2 after COVID‐19 vaccination—Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1081‐1083.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8360277</ArticleId>
            <ArticleId IdType="pubmed">34383732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Menni C, Klaser K, May A, et al. Vaccine side‐effects and SARS‐CoV‐2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21:939‐949.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8078878</ArticleId>
            <ArticleId IdType="pubmed">33930320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bergwerk M, Gonen T, Lustig Y, et al. Covid‐19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474‐1484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8362591</ArticleId>
            <ArticleId IdType="pubmed">34320281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaneko S, Kurosaki M, Sugiyama T, et al. The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination. J Med Virol. 2021;93:6813‐6817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8427121</ArticleId>
            <ArticleId IdType="pubmed">34314037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS‐CoV‐2 infection on humoral and T‐cell responses to single‐dose BNT162b2 vaccine. Lancet. 2021;397:1178‐1181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7993933</ArticleId>
            <ArticleId IdType="pubmed">33640037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Callegaro A, Borleri D, Farina C, et al. Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection. J Med Virol. 2021;93:4612‐4615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8250392</ArticleId>
            <ArticleId IdType="pubmed">33788281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID‐19. Nature. 2021;595:283‐288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34010947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Proal AD, VanElzakker MB. Long COVID or post‐acute sequelae of COVID‐19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8260991</ArticleId>
            <ArticleId IdType="pubmed">34248921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Garcia‐Abellan J, Padilla S, Fernandez‐Gonzalez M, et al. Antibody response to SARS‐CoV‐2 is associated with long‐term clinical outcome in patients with COVID‐19: a longitudinal study. J Clin Immunol. 2021;41:1490‐1501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8285689</ArticleId>
            <ArticleId IdType="pubmed">34273064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Are vaccines safe in patients with Long COVID? A prospective observational study. Medrxiv. 2021. 10.1101/2021.03.11.21253225
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.03.11.21253225</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
